Valeant Pharma Posts Answers To Refute Allergan's (AGN) Misleading Statements
US IMS data will cover less than 30% of Valeant's business and, for that portion of Valeant's business IMS covers, the IMS data will not properly collect sales through a numbers of channels (e.g., specialty pharmacy, physician dispensed sales, corporate accounts, and alternative fulfillment).
In Q1 2014, quarter over comparable quarter in Q1 2013 o 13 of the top 15 Valeant products are growing : Wellb utrin XL, Renu, Solodyn, Xenazine, Ocuvite, Preservision, Lotemax Gel, Elidel, BioTrue Solution, Artelac, CeraVe, Syprine, and Acanya o 9 of the 15 are growing by volume : Renu, Xenazine, Ocuvite, Preservision, Lotemax Gel, Elidel, BioTrue Solutions , Artelac , CeraVe o Two products that are not growing are Zovirax (impacted by generic competition) and Boston Solution
In Q1 2014, quarter over comparable quarter in Q1 2013 o 13 of the top 15 Valeant products are growing : Wellb utrin XL, Renu, Solodyn, Xenazine, Ocuvite, Preservision, Lotemax Gel, Elidel, BioTrue Solution, Artelac, CeraVe, Syprine, and Acanya o 9 of the 15 are growing by volume : Renu, Xenazine, Ocuvite, Preservision, Lotemax Gel, Elidel, BioTrue Solutions , Artelac , CeraVe o Two products that are not growing are Zovirax (impacted by generic competition) and Boston Solution
See attached fot full dertails